- Home
- KPTI vs ZENV Comparison
KPTI vs ZENV Comparison
Compare KPTI & ZENV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPTI
- ZENV
- Stock Information
- Founded
- KPTI 2008
- ZENV 2005
- Country
- KPTI United States
- ZENV Brazil
- Employees
- KPTI N/A
- ZENV N/A
- Industry
- KPTI Biotechnology: Pharmaceutical Preparations
- ZENV Computer Software: Prepackaged Software
- Sector
- KPTI Health Care
- ZENV Technology
- Exchange
- KPTI Nasdaq
- ZENV Nasdaq
- Market Cap
- KPTI 103.5M
- ZENV 63.3M
- IPO Year
- KPTI 2013
- ZENV 2021
- Fundamental
- Price
- KPTI $0.64
- ZENV $1.62
- Analyst Decision
- KPTI Strong Buy
- ZENV
- Analyst Count
- KPTI 4
- ZENV 0
- Target Price
- KPTI $5.00
- ZENV N/A
- AVG Volume (30 Days)
- KPTI 1.0M
- ZENV 73.5K
- Earning Date
- KPTI 11-05-2024
- ZENV 11-18-2024
- Dividend Yield
- KPTI N/A
- ZENV N/A
- EPS Growth
- KPTI N/A
- ZENV N/A
- EPS
- KPTI N/A
- ZENV N/A
- Revenue
- KPTI $148,442,000.00
- ZENV $173,594,726.00
- Revenue This Year
- KPTI $6.67
- ZENV $25.56
- Revenue Next Year
- KPTI $8.58
- ZENV $6.02
- P/E Ratio
- KPTI N/A
- ZENV N/A
- Revenue Growth
- KPTI 1.77
- ZENV 23.49
- 52 Week Low
- KPTI $0.63
- ZENV $1.00
- 52 Week High
- KPTI $1.95
- ZENV $3.88
- Technical
- Relative Strength Index (RSI)
- KPTI 25.28
- ZENV 54.93
- Support Level
- KPTI $0.75
- ZENV $1.61
- Resistance Level
- KPTI $0.83
- ZENV $1.78
- Average True Range (ATR)
- KPTI 0.05
- ZENV 0.12
- MACD
- KPTI -0.01
- ZENV -0.00
- Stochastic Oscillator
- KPTI 4.21
- ZENV 48.48
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.